TargEDys and SymbioPharm enter an exclusive partnership to launch SymbioLife(R) Satylia(R) in Germany
PR99016
PARIS, Nov. 29, 2022 /PRNewswire=KYODO JBN/ --
TargEDys and SymbioPharm signed an exclusive marketing and distribution
agreement for the launch of SymbioLife(R) Satylia(R) in Germany. The novel
dietary supplement based on the next-generation probiotic Hafnia alvei HA4597
will be available from January 2023.
SymbioLife(R) Satylia(R) is a precision probiotic with a characterized
mechanism of action at molecular level: it increases satiety thanks to the
protein ClpB produced by Hafnia alvei HA4597. ClpB naturally mimics the human
satiety hormone alpha-MSH. The improved feeling of satiety helps with
successful weight loss, as confirmed by a clinical study with 230 overweight
adults. This natural principle provided by SymbioLife(R) Satylia(R) is a
multi-awarded new, natural, safe and effective weight management solution.
Gregory Lambert, CEO of TargEDys: "We are extremely proud and excited about
this new collaboration. SymbioPharm is in the top 3 of the German probiotics
market and fathered one of the first probiotic pharmaceuticals globally. With
the team's knowledge of probiotic Enterobacteria, their strong position with
doctors, pharmacies, and synergies with probiotics and diagnostics, they are
the perfect partner for this highly scientific product."
Juergen Eck, Co-CEO and CTO of SymbioPharm:
"We are very excited to partner with TargEDys and work together on a new era of
evidence-based probiotics. With the patent-protected probiotic Hafnia alvei
HA4597, its biological mechanism of action and outstanding studies, we can
offer an effective solution for the growing problems of obesity and metabolic
health. As pioneers in microbiome research and medical probiotics, we are proud
to now also help shape the introduction of knowledge-based precision
probiotics."
About SymbioPharm
SymbioPharm GmbH is a pioneer in microbiome research and knowledge-based
probiotics - since 1954. Its mission is to preserve health and to heal diseases
with probiotic bacteria – making use of purely biological effect of natural
bacteria. Therefore, it researches the human microbiome and develops innovative
microbiological therapy approaches. The company holds a state-of-the-art
production facility, and showcases comprehensive expertise from diagnostics –
with the Institute for Microecology – to innovative solutions.
www.symbiopharm.de
About TargEDys(R)
TargEDys(R) is a commercial-stage French biotech specialized in the development
of nutraceutical solutions through microbiome interventions. The company is
based on 15 years of research on the microbiota conducted within academic
laboratories. TargEDys(R)' portfolio focuses on overweight, undernutrition, and
mental health, all based on the concept of PreciBiomic strains backed by a
molecular mechanism of action and in vivo studies.
www.targedys.com
Contact:
Arnaud Faure & Nina Vinot
bd@targedys.com
Logo - https://mma.prnewswire.com/media/1956913/TargEDys_SymbioPharm_Logo.jpg
SOURCE: TargEDys
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。